Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. حسب Alejandro Piscoya (782326)

الموضوعات:

Description of characteristics of included studies. حسب Alejandro Piscoya (782326)

الموضوعات:

Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. حسب Alejandro Piscoya (782326)

الموضوعات:

Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19. حسب Alejandro Piscoya (782326)

الموضوعات:

Representative images of identifying CVH by ICGA and superimposing retinal sensitivity. حسب Rion Ozawa (13155216)

Metformin pre-treatment retains an antioxidant effect and decreases apoptosis, in an AMPK activation manner. حسب Silvia Siteni (10344070)

Effect of selected feed additives to improve growth and health of dairy calves حسب Luisa F. L. Salazar (6664121)

"…The treatments were: control (CON), monensin (MON; 30 mg/kg of starter), probiotic <i>E</i>. <i>faecium</i> (PROB; 70 mg/kg of starter), essential oils (EO; 300 mg/kg of starter), or PROB + EO (EOPROB). …"

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

Fig 2 - حسب Nida Mansoora (11648641)

الموضوعات:

Fig 3 - حسب Nida Mansoora (11648641)

الموضوعات:

Fig 4 - حسب Nida Mansoora (11648641)

الموضوعات:

Fig 1 - حسب Nida Mansoora (11648641)

الموضوعات:

Effect of different treatments on ionic contents like sodium, calcium, potassium, phosphorous and soluble proteins constituents of two wheat genotypes (Markaz 19 and Ujala 16) afte... حسب Nida Mansoora (11648641)

الموضوعات:

Participants with virologic suppression or failure at week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات: